By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, ...
Vietnam Investment Review on MSN
Alar reports positive phase 1 results for long acting ketamine therapy
TAICHUNG, April 6, 2026 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced ...
A dog meets a hydrant. Another meets a dog. One repeats, the other one risks. The difference isn’t small,it’s the difference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results